IXHL

IXHL

Incannex Healthcare Ltd ADR

Net -17.58%top 1%Rev -22.54%top 1%1Y
Hold

Incannex Healthcare develops psychedelic and cannabinoid medicines, targeting chronic diseases. Its pipeline includes treatments for obstructive sleep apnea, generalized anxiety disorder, and inflammatory conditions, with multiple products in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2022 $ AUD
$1,000 invested 1 year ago โ†’$250today

Score Overview

1 Year
Scoreโ€”
Net Growth-17.58%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-22.54%
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-437.69%
Net Trend25%
Net Income Consistency
Rev Growth-87.67%
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Incannex Healthcare Ltd ADR fundamental performance

Across Incannex Healthcare Ltd ADR's full reported history, from 2022 to 2025, revenue declined from $ 540.17K to $ 86K and net income went from -$ 10M to -$ 46M. Revenue increased in 50% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 3.17โ€”
1 Year2025-08-12
$ 12.66-74.96%
All Time2022-03-02
$ 1.79K-99.82%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 66.62K-$ 55M$ 68M
2025$ 86K-$ 46M$ 15M
2024$ 17.96K-$ 27M$ 5M
2023$ 1M-$ 48M$ 22M
IPO2022$ 540.17K-$ 10M$ 25M

Explore beyond IXHL

You're looking at Incannex Healthcare Ltd ADR. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies